Refuted claims from observational studies often persist despite strong evidence against them

December 04, 2007

Prominent claims from observational studies of the cardiovascular benefits of vitamin E often continue to be supported in medical literature despite strong contradictory evidence from randomized trials, according to a study in the December 5 issue of JAMA. Similar findings were found for claims regarding the protective effects of beta-carotene on cancer and estrogen on Alzheimer disease.

"Some research findings that have received wide attention in the scientific community, as proven by the high citation counts of the respective articles, are eventually contradicted by subsequent evidence. A number of such high-profile contradictions pertain to differences between nonrandomized and randomized studies," the authors write. Despite these contradictions, findings from observational trials may still be supported in some scientific circles.

Athina Tatsioni, M.D., of the University of Ioannina School of Medicine, Ioannina, Greece, and colleagues evaluated the change in favorable vs. unfavorable citations for two highly cited epidemiological studies that proposed major cardiovascular benefits associated with vitamin E in 1993, which were strongly contradicted by evidence from large randomized clinical trials (RCTs). To assess the generalizability of these findings, the researchers also examined the extent to which two other major contradicted claims, the effectiveness of beta-carotene for preventing cancer and of estrogens for preventing Alzheimer dementia, continue to be supported in the current medical literature.

For the vitamin E claims, the researchers sampled articles published in 1997, 2001, and 2005 (before, early, and late after publication of refuting evidence) that referenced the highly cited epidemiological studies and separately sampled articles published in 2005 and referencing the major contradicting RCT (HOPE trial). They also sampled articles published in 2006 that referenced highly cited articles proposing benefits associated with beta-carotene for cancer (published in 1981 and contradicted by RCTs in 1994-1996) and estrogen for Alzheimer disease (published in 1996 and contradicted by RCTs in 2004).

The researchers found that for the two vitamin E epidemiological studies, even in 2005, 50 percent of citing articles remained favorable. A favorable stance was independently less likely in more recent articles, specifically in articles that also cited the HOPE trial and in general/internal medicine vs. specialty journals. In a sample of 29 articles published in 2005 that had cited the HOPE study, six (20.7 percent) were still favorable to vitamin E, 11 (37.9 percent) were equivocal (uncertain), and 12 (41.4 percent) were unfavorable. "Even among articles that cited the contradicting HOPE trial rather than the positive epidemiological studies, the majority in 2005 still could not conclude that vitamin E was ineffective," the authors write.

Regarding the claims for beta-carotene, 10 citing articles (62.5 percent) were favorable, three (18.8 percent) equivocal, and three (18.8 percent) unfavorable. For estrogen, 29 citing articles (61.7 percent) were favorable, 14 (29.8 percent) equivocal, and 4 (8.5 percent) unfavorable. All beta-carotene citations and all but two estrogen citations appeared in specialty journals.

"Counterarguments defending vitamin E or estrogen included diverse selection and information biases and genuine differences across studies in participants, interventions, co-interventions, and outcomes. Favorable citations to beta-carotene, long after evidence contradicted its effectiveness, did not consider the contradicting evidence."

"... it can be difficult to discern whether perpetuated beliefs are based on careful consideration of all evidence and differential interpretation, inappropriate entrenchment of old information, lack of dissemination of newer data, or purposeful silencing of their existence. Regardless of the reasons, better communication between research specialists and evidence-based clinical science may improve this situation and may lead to more rational and concerted translational efforts in basic, pre-clinical, and clinical research," the researchers conclude.
-end-
(JAMA. 2007;298(21):2517-2526. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.